Clinical Activity of Daratumumab Monotherapy in Heavily Pretreated RRMM

Conference Correspondent  - Conference Correspondent, ASH

Usmani and colleagues reported on the results of a combined efficacy analysis of patients treated with the anti-CD38 monoclonal antibody daratumumab in 2 trials, Sirius and part 2 of GEN501 trials, of patients with relapsed/refractory multiple myeloma (RRMM).1 Sirius is a 2-part, randomized phase 2 study in patients who had received ≥3 prior therapies, including a proteasome inhibitor or immunomodulatory drug, or were refractory to both these drug classes. GEN501 is a 2-part (part 1, dose escalation; part 2, dose expansion) study in patients who had relapsed after or were refractory to ≥2 prior therapies. The study population included 148 patients; 42 patients were from the GEN501 trial and 106 were from the Sirius trial. In the combined analysis, patients achieved an objective response rate (ORR) of 31% and ≥very good partial response rate of 10%; 1% of patients achieved complete responses (CRs) and 2% achieved stringent CRs. At a median follow-up of 9.3 months, the median duration of response in the combined analysis was 7.6 months, and the 1-year progression-free survival was 46% among responders. At a median follow-up of 14.8 months, the estimated median overall survival (OS) was 19.9 months in the combined analysis; the estimated 1-year OS rate was 69%. The efficacy outcomes in the individual GEN501 trial were similar, the ORR was 36%, the estimated 1-year OS rate was 77%, and median OS had not been reached at a median follow-up of 10.2 months. In the Sirius trial, an ORR of 36% was reported, the estimated 1-year OS rate was 65%, and median OS had not been reached at median follow-up of 9.3 months. Overall, it was concluded that the results of the combined analysis supported the individual study results in demonstrating a robust clinical activity of daratumumab monotherapy in heavily pretreated patients with RRMM. Based primarily on these data, daratumumab monotherapy was approved on November 16, 2015, for the treatment of patients with MM who have received at least 3 prior treatments. Daratumumab is the first monoclonal antibody approved for the treatment of MM.

  1. Usmani S, et al. ASH 2015. Abstract 29.
Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: April 27, 2020